Navidea Biopharmaceuticals INAVBQ
13F holders, Q1 2025 (March 31)2holders +1
1new positions
0sold out
$0.00avg. 13F price*
At the end of Q1 2025, 2 institutions reported holding Navidea Biopharmaceuticals I (NAVBQ) in their 13F filings, up 1 from Q4 2024. 1 opened new positions and 0 sold out. The largest holders were Ancora Advisors LLC ($0) and Runnymede Capital Advisors, Inc. ($0).
- Company
- Navidea Biopharmaceuticals I
- CUSIP
- 63937X202
- Latest filing quarter
- Q4 2025
History
Number of 13F holders
Total Exit/New Position Q4 2024 → Q1 2025
| Institutions | Total Value | |
|---|---|---|
| New Positions | 1 | $0 |
| Exits | 0 | $0 |
All 13F filers, Q4 2024 → Q1 2025: 100 shares bought, net +100 shares. Counts holders who added, trimmed, opened or closed a position; split-adjusted.
Ownership 2 holders
| Ancora Advisors LLC | 0.00% | New | 100 | $0 |
| Runnymede Capital Advisors, Inc. | 0.00% | No change | 5 | $0 |
"% of holder's portfolio" is NAVBQ's weight in each manager's 13F, not the share of Navidea Biopharmaceuticals I the manager owns.